Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
About this item
Full title
Author / Creator
Publisher
Egypt: Hindawi Publishing Corporation
Journal title
Language
English
Formats
Publication information
Publisher
Egypt: Hindawi Publishing Corporation
Subjects
More information
Scope and Contents
Contents
Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those with progressive or clinically advanced disease will...
Alternative Titles
Full title
Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4003830
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4003830
Other Identifiers
ISSN
2090-5661,2090-567X
E-ISSN
2090-567X
DOI
10.1155/2014/931858
